
Zymeworks Inc (ZYME) Stock Forecast & Price Target
Zymeworks Inc (ZYME) Analyst Ratings
Bulls say
Zymeworks Inc. has received FDA accelerated approval for its therapeutic candidate, zanidatamab, for treating adults with metastatic HER2-positive biliary tract cancer, showcasing a strong 52% objective response rate and a median duration of response of 14.9 months. The approval not only bolsters Zymeworks's clinical standing but also results in a $25 million milestone payment to the company, enhancing its financial position. Furthermore, the drug's promising clinical outcomes, such as a median progression-free survival of 7.2 months and median overall survival ranging from 15.5 to 18.1 months for certain patient groups, suggest strong potential for future growth and revenue generation in the biopharmaceutical market.
Bears say
Zymeworks Inc faces multiple challenges that contribute to a negative outlook, including difficulties in scaling up manufacturing for biparatopic antibodies and potential delays in the timely approval of its lead candidate, zanidatamab. The company has projected a significant net loss of $1.95 per share for full-year 2025, which reflects a deterioration in financial performance with a wider loss reported in Q4 2024 than previously anticipated. Additional concerns include risks related to partnership outcomes, lower commercial uptake than expected, and the possibility of long-term dilution, which further complicate the company's financial prospects.
This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.
Zymeworks Inc (ZYME) Analyst Forecast & Price Prediction
Start investing in Zymeworks Inc (ZYME)
Order type
Buy in
Order amount
Est. shares
0 shares